Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of diabetes
3.2.1.2 Rising geriatric population
3.2.1.3 Technological advancements
3.2.1.4 Rising awareness and screening programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment cost
3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Diabetic retinopathy
5.3 Macular degeneration
5.3.1 Dry macular degeneration
5.3.2 Wet macular degeneration
5.4 Diabetic macular edema
5.5 Retinal vein occlusion
5.6 Other types
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Capsules & tablets
6.3 Eye drops
6.4 Eye solutions
6.5 Gels
6.6 Ointments
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Alimera Sciences, Inc.
9.3 Alcon, Inc.
9.4 Bayer AG
9.5 Biogen Inc.
9.6 Bausch Health Companies
9.7 F. Hoffmann-La Roche Ltd.
9.8 Graybug Vision, Inc.
9.9 Merck & Co., Inc.
9.10 Novartis AG
9.11 Ophthotech Corporation
9.12 Pfizer, Inc.
9.13 Regeneron Pharmaceuticals Inc.
9.14 Santen Pharmaceuticals Co. Ltd.
9.15 Takeda Pharmaceutical Company Limited
